All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The MPN Hub

Brought to you by Scientific Education Support

Scientific Education Support

The MPN Hub is an independent medical education platform, sponsored by GSK, Novartis, AOP, Sobi and Takeda and supported through independent educational grants from Bristol Myers Squibb, Blueprint Medicines, Incyte and Merck Sharp & Dohme LLC, Rahway, NJ, USA. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My MPN Hub

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View MPN content recommended for you

MPNCo&D Congress 2022

Share:

Nov 12, 2022

X post image

12 May 2023

Have you read this?
#MpncoD22 | What are the key toxicities and potential limitations associated with JAKi-based MF combination therapies in clinical practice? To find out more, read our summary.
👉 https://t.co/gxbbGr8nGa
#mpnsm #mpn

X post image

29 Dec 2022

#MpncoD22 | What are the key toxicities and potential limitations associated with JAKi-based MF combination therapies in clinical practice? To find out more, read our summary of recent expert presentations at the MPNCo&D 2022 Congress.
👉 https://t.co/gxbbGr8nGa
#mpnsm #mpn

X post image

22 Dec 2022

#MpncoD22 | During @MpncoD, @MPNlab gave a presentation on novel approaches to manage inflammation associated with #MPN. Check out our summary of the talk here 👇 https://t.co/I6SCIAk3SS
#MPNsm

X post image

12 Nov 2022

#MpncoD22| @DJ_Royston @UniofOxford gives a talk on the use of AI/machine learning for the clinical management of MPNs. He highlights megakaryocyte analysis, fibrosis feature analysis and future directions.
#medicalcongress #MPN #mpnsm @MpncoD

X post image

12 Nov 2022

#MpncoD22| @JoeKhouryMD @unmc gives an overview of the WHO classification in MPNs and the evolving paradigms associated with sub type classification.
#medicalcongress #MPN #mpnsm @MpncoD

X post image

12 Nov 2022

#MpncoD22|@jyoti_nangalia @CUH_NHS gives a presentation on how MPN mutations start younger than intially thought, highlighting in utero observations and phylogenetic approaches to better understand the mutational timeline.
#medicalcongress #MPN #mpnsm @MpncoD

X post image

12 Nov 2022

#MpncoD22|@MPNlab University of California discusses the role of inflammation in MPN and the anti inflammatory effects of certain therapies, optimising gut microbiome health and diet intervention.
#medicalcongress #MPN #mpnsm @MpncoD

X post image

12 Nov 2022

#MpncoD22|@DavidSteensma @NovartisScience discusses clonal hematopoiesis. He highlights the impact of somatic JAK2 mutations and future treatment directions.
#medicalcongress #MPN #mpnsm @MpncoD

X post image

12 Nov 2022

#MpncoD22| @DeeptiRadia @G_ICEMD gives a talk on the emerging treatment approaches for patients with systemic mastocytosis. She highlights results from recent clinical trials, future directions and current controversies.
#medicalcongress #MPN #mpnsm @MpncoD

X post image

12 Nov 2022

#MpncoD22| Jason Gotlib @StanfordMed presents recent updates in the classification of eosinophilic and mast cell disorders. He highlights diagnostic considerations, associated mutations and the distinguishment between sub types.
#medicalcongress #MPN #mpnsm @MpncoD

X post image

11 Nov 2022

#MpncoD22|@GabbyHobbs @MGHCancerCenter gives a presentation on unique considerations needed for thromboses in young patients with MPN. She highlights treatment choices, current prognostic guidelines and areas needing further investigation.
#medicalcongress #MPN #mpnsm @MpncoD

X post image

11 Nov 2022

#MpncoD22|@PedsHemeDoc @WeillCornell gives an overview of paediatric and adolescent and young adult patients with MPN. She highlights key areas of consideration including genetics, prevention and management of thrombotic events and treatment.
#medicalcongress #MPN #mpnsm @MpncoD

X post image

11 Nov 2022

#MpncoD22| @AaronGerds @caseccc gives a presentation on toxicities and complications that need to be monitored with the introduction of combination therapies. He highlights potential toxicity limiting efficacy and compounding toxic effects.
#medicalcongress #MPN #mpnsm @MpncoD

X post image

11 Nov 2022

#MpncoD22|@doctorpemm @MDAndersonNews discusses important considerations in the management of patients with combination therapies. He focuses on BET, BCXL and JAK inhibitor approaches and combinations.
#medicalcongress #MPN #mpnsm @MpncoD

X post image

11 Nov 2022

#MpncoD22|@doctorpemm @MDAndersonNews discusses anaemia in myelofibrosis and emerging clinical approaches. He highlights several studies and their impact on the treatment landscape.
#medicalcongress #MPN #mpnsm @MpncoD

X post image

11 Nov 2022

#MpncoD22| Srdan Verstovsek @MDAndersonNews discusses the current treatment options for high-risk myelofibrosis. In particular, he highlights the considerations associated with optimising ruxolitinib, fedratinib and pacritinib therapy.
#medicalcongress #MPN #mpnsm @MpncoD

X post image

11 Nov 2022

#MpncoD22|@MullalyLab @harvardmed discusses the immunological approaches to target mutant CALR. She highlights potential antibody therapies and T cell approaches.
#medicalcongress #MPN #mpnsm @MpncoD

X post image

11 Nov 2022

#MpncoD22| Ian Hitchcock @UniOfYork discusses the importance of the driver mutation CALR in MPN. He highlights the molecular genetics, mechanism of action, clinical features and potential treatment opportunities.
#medicalcongress #MPN #mpnsm @MpncoD

X post image

11 Nov 2022

#MpncoD22| @harrisoncn1 @GSTTnhs discusses the state of the art management of high-risk essential thrombocythemia. She highlights the important considerations associated with common treatments as well as the potential of some novel therapies.
#medicalcongress #MPN #mpnsm @MpncoD

X post image

11 Nov 2022

#MpncoD22|@Mdmasarova @MDAndersonNews and Alessandro Vannucchi @UNI_FIRENZE debates the use of low dose aspirin as the standard of care in the treatment of essential thrombocythemia
#medicalcongress #MPN #mpnsm @MpncoD

X post image

11 Nov 2022

#MpncoD22| Ronal Hoffman @IcahnMountSinai discusses the role of hepcidin mimetics, in particular rusfertide, anti-sense oligonucleotides and siRNA. He highlights results from the REVIVE trial and future trials evaluating these novel therapies
#medicalcongress #MPN #mpnsm @MpncoD

X post image

11 Nov 2022

#MpncoD22|@jjkiladjian @HopSaintLouis gives an update on ropeginterferon use in 2022. He highlights results from the PROUD and CONTINUATION trials investigating ropeginterferon compared to HU in patients with PV.
#medicalcongress #MPN #mpnsm @MpncoD

X post image

11 Nov 2022

#MpncoD22|Richard Silver @WeillCornell and Brady Stein debates the current standard of care in polycythemia vera, highlighting when to treat and what agents to use.
#medicalcongress #MPN #mpnsm @MpncoD

<span> </span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

MPNCo&D 2022 Myeloproliferative Neoplasms Controversies and Debates Congress

Your opinion matters

Do you include basal serum tryptase (bST) testing in the diagnostic evaluation of patients with MPN?

Newsletter

Subscribe to get the best content delivered to your inbox